330 related articles for article (PubMed ID: 2418353)
21. The inotropic effects of amrinone and milrinone on neonatal and young canine cardiac muscle.
Binah O; Sodowick B; Vulliemoz Y; Danilo P; Rosen M
Circulation; 1986 Mar; 73(3 Pt 2):III46-51. PubMed ID: 3002663
[TBL] [Abstract][Full Text] [Related]
22. [New positive inotropic drugs in acute and chronic heart failure].
Follath F
Schweiz Rundsch Med Prax; 1992 May; 81(21):704-7. PubMed ID: 1351309
[TBL] [Abstract][Full Text] [Related]
23. Differential inhibition of cardiac cyclic nucleotide phosphodiesterase isozymes by cardiotonic drugs.
Harrison SA; Chang ML; Beavo JA
Circulation; 1986 Mar; 73(3 Pt 2):III109-16. PubMed ID: 3002661
[TBL] [Abstract][Full Text] [Related]
24. Enoximone (MDL 17,043), a phosphodiesterase inhibitor, in the treatment of advanced, unstable chronic heart failure.
Weber KT; Janicki JS; Jain MC
J Heart Transplant; 1986; 5(2):105-12. PubMed ID: 2956397
[TBL] [Abstract][Full Text] [Related]
25. [Effects of R80122. The influence of a new phosphodiesterase inhibitor on global and intestinal hemodynamics in coronary surgery patients].
Lange H; Stephan H; Autschbach R; Lueerssen K; Zielmann S; Sonntag H
Anaesthesist; 1992 Aug; 41(8):474-80. PubMed ID: 1524159
[TBL] [Abstract][Full Text] [Related]
26. Phosphodiesterase-inhibiting properties of newer inotropic agents.
Scholz H; Meyer W
Circulation; 1986 Mar; 73(3 Pt 2):III99-108. PubMed ID: 2417748
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of a new bipyridine inotropic agent--milrinone--in patients with severe congestive heart failure.
Baim DS; McDowell AV; Cherniles J; Monrad ES; Parker JA; Edelson J; Braunwald E; Grossman W
N Engl J Med; 1983 Sep; 309(13):748-56. PubMed ID: 6888453
[TBL] [Abstract][Full Text] [Related]
28. Isolation and characterization of bovine cardiac muscle cGMP-inhibited phosphodiesterase: a receptor for new cardiotonic drugs.
Harrison SA; Reifsnyder DH; Gallis B; Cadd GG; Beavo JA
Mol Pharmacol; 1986 May; 29(5):506-14. PubMed ID: 3010079
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics of the bipyridines amrinone and milrinone.
Edelson J; Stroshane R; Benziger DP; Cody R; Benotti J; Hood WB; Chatterjee K; Luczkowec C; Krebs C; Schwartz R
Circulation; 1986 Mar; 73(3 Pt 2):III145-52. PubMed ID: 3510771
[TBL] [Abstract][Full Text] [Related]
30. Comparative effects of R 80122, enoximone, and milrinone on left ventricular phosphodiesterase isoenzymes in vitro and on contractility of normal and stunned myocardium in vivo in dogs.
Vandeplassche GM; Hermans CF; de Chaffoy de Courcelles DR; D'Aubioul JA; Wouters LJ; De Clerck FF
J Cardiovasc Pharmacol; 1992 May; 19(5):714-22. PubMed ID: 1381769
[TBL] [Abstract][Full Text] [Related]
31. Milrinone: a positive inotropic vasodilator.
Colucci WS; Jaski BE; Fifer MA; Wright RF; Braunwald E
Trans Assoc Am Physicians; 1984; 97():124-33. PubMed ID: 6535335
[No Abstract] [Full Text] [Related]
32. Pharmacology of the bipyridines: amrinone and milrinone.
Alousi AA; Johnson DC
Circulation; 1986 Mar; 73(3 Pt 2):III10-24. PubMed ID: 2417744
[TBL] [Abstract][Full Text] [Related]
33. [Old and new positive inotropic drugs: problems and controversies].
Cocco G; Strozzi C; Tasini MT; Padula A; Urso L; Rizzo A; Alfiero R
Minerva Cardioangiol; 1984 Nov; 32(11):831-42. PubMed ID: 6152331
[No Abstract] [Full Text] [Related]
34. [Phosphodiesterase inhibition as a new positive-inotropic principle].
Hartmann A; Saeed M; Sütsch G; Bing RJ
Dtsch Med Wochenschr; 1986 Dec; 111(51-52):1971-7. PubMed ID: 3539571
[No Abstract] [Full Text] [Related]
35. [The hemodynamic profile of amrinone and enoximone in patients with severe heart failure].
Saborowski F; Peters P; Schneider M
Z Kardiol; 1991; 80 Suppl 4():63-7. PubMed ID: 1833900
[TBL] [Abstract][Full Text] [Related]
36. Amrinone--a new inotropic agent in chronic resistant congestive cardiac failure.
Robinson PJ; Lvoff R; Chong B; Barrett PA
Aust N Z J Med; 1981 Dec; 11(6):666-8. PubMed ID: 6949545
[TBL] [Abstract][Full Text] [Related]
37. Positive inotropic therapy for short-term support and long-term management of patients with congestive heart failure: hemodynamic effects and clinical efficacy of MDL 17,043.
Uretsky BF; Valdes AM; Reddy PS
Circulation; 1986 Mar; 73(3 Pt 2):III219-29. PubMed ID: 2935328
[TBL] [Abstract][Full Text] [Related]
38. [Rational and irrational approach to the inotropic agent therapy of heart failure].
Colombo F; Libretti A
Clin Ter; 1988 Sep; 126(6):421-6. PubMed ID: 2974404
[No Abstract] [Full Text] [Related]
39. General overview and update of positive inotropic therapy.
Leier CV
Am J Med; 1986 Oct; 81(4C):40-5. PubMed ID: 2946223
[TBL] [Abstract][Full Text] [Related]
40. Long-term oral therapy of congestive heart failure with phosphodiesterase inhibitors.
Wood MA; Hess ML
Am J Med Sci; 1989 Feb; 297(2):105-13. PubMed ID: 2521982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
